308 related articles for article (PubMed ID: 19366571)
1. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease.
Sorichter S; Baumann U; Baumgart A; Walterspacher S; von Specht BU
Vaccine; 2009 May; 27(21):2755-9. PubMed ID: 19366571
[TBL] [Abstract][Full Text] [Related]
2. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.
Bumann D; Behre C; Behre K; Herz S; Gewecke B; Gessner JE; von Specht BU; Baumann U
Vaccine; 2010 Jan; 28(3):707-13. PubMed ID: 19887136
[TBL] [Abstract][Full Text] [Related]
3. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
[TBL] [Abstract][Full Text] [Related]
4. Vaccines and immunotherapy against Pseudomonas aeruginosa.
Döring G; Pier GB
Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
[TBL] [Abstract][Full Text] [Related]
5. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
[TBL] [Abstract][Full Text] [Related]
6. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
Front Immunol; 2019; 10():2497. PubMed ID: 31708925
[No Abstract] [Full Text] [Related]
7. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis.
Döring G; Dorner F
Behring Inst Mitt; 1997 Feb; (98):338-44. PubMed ID: 9382758
[TBL] [Abstract][Full Text] [Related]
8. Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa.
Gilleland HE; Gilleland LB; Staczek J; Harty RN; Garcia-Sastre A; Engelhardt OG; Palese P
Behring Inst Mitt; 1997 Feb; (98):291-301. PubMed ID: 9382753
[TBL] [Abstract][Full Text] [Related]
9. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
[TBL] [Abstract][Full Text] [Related]
10. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
[TBL] [Abstract][Full Text] [Related]
11. Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.
Gartner T; Baeten M; Otieno S; Revets H; De Baetselier P; Huygen K
Immunol Lett; 2007 Jul; 111(1):26-35. PubMed ID: 17570535
[TBL] [Abstract][Full Text] [Related]
12. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study.
Pressler T; Frederiksen B; Skov M; Garred P; Koch C; Høiby N
J Cyst Fibros; 2006 Jan; 5(1):9-15. PubMed ID: 16412706
[TBL] [Abstract][Full Text] [Related]
13. Mucosal immunity to Pseudomonas aeruginosa alginate in cystic fibrosis.
Pedersen SS; Møller H; Espersen F; Sørensen CH; Jensen T; Høiby N
APMIS; 1992 Apr; 100(4):326-34. PubMed ID: 1581041
[TBL] [Abstract][Full Text] [Related]
14. A specific serum IgA antibody discriminates pneumonia from colonization state in patients with Pseudomonas aeruginosa in sputum culture.
Yamashita M; Hida Y; Sugimoto H; Takahashi N; Kimura H; Nakatomi Y; Yoshida H; Ishizaki T
J Microbiol Methods; 2010 Sep; 82(3):198-204. PubMed ID: 20538018
[TBL] [Abstract][Full Text] [Related]
15. Vaccine strategies against Pseudomonas aeruginosa infection in the lung.
Cripps AW; Dunkley ML; Clancy RL; Kyd J
Behring Inst Mitt; 1997 Feb; (98):262-8. PubMed ID: 9382749
[TBL] [Abstract][Full Text] [Related]
16. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G; Shand GH; Fomsgaard A; Høiby N
APMIS; 1992 Feb; 100(2):175-80. PubMed ID: 1554493
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.
Arnold H; Bumann D; Felies M; Gewecke B; Sörensen M; Gessner JE; Freihorst J; von Specht BU; Baumann U
Infect Immun; 2004 Nov; 72(11):6546-53. PubMed ID: 15501786
[TBL] [Abstract][Full Text] [Related]
19. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
Göcke K; Baumann U; Hagemann H; Gabelsberger J; Hahn H; Freihorst J; von Specht BU
FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):167-71. PubMed ID: 12832121
[TBL] [Abstract][Full Text] [Related]
20. [Serum level of Pseudomonas aeruginosa-specific IgA in patients with chronic lower respiratory tract infection and its clinical significance].
Tsukada H; Suzuki E; Wada K; Arakawa M
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Oct; 31(10):1227-34. PubMed ID: 8271654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
